Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

NCT02736955 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
161
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Neurocrine Biosciences